Moderna reports Q2 loss of $782M, cuts 2026 opex by ~$200M, awaits Aug 5 flu vaccine decision

Filed July 31, 2026 · Period ending July 31, 2026 · ~1 min read

Key Changes

• high

  Q2 2026 revenue $145M (flat YoY); net loss $782M or $(1.97)/share, improved 5% from Q2 2025 on lower operating expenses despite continued weak COVID vaccine sales

  Exhibit 99.1 view on EDGAR →
• high

  Flu vaccine mFLUSIVA received unanimous FDA advisory committee recommendation; PDUFA decision Aug 5, 2026—would be Moderna's fifth approved product and first non-COVID commercial vaccine

  Exhibit 99.1 view on EDGAR →
• high

  Lowered 2026 R&D guidance to ~$2.9B (from $3.0B) and cost of sales to ~$1.7B (from $1.8B); improved projected year-end cash to $4.7-5.2B, ~$200M better than prior outlook

  Exhibit 99.1 view on EDGAR →